NASDAQ · Biotechnology

MBIO (MBIO) Stock

$0.57 -3.97% NASDAQ: MBIO Healthcare

Valuation

MetricValue
Price$0.57
Market Cap$4.32M
P/E Ratio-1.56
P/B Ratio0.46
P/S Ratio0.00
EPS (TTM)$-0.39
52-Week High$7.00
52-Week Low$0.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-20.00%
ROA-11.11%
ROCE-20.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-67.0M$-76.0M$-51.0M$-16.0M$-2.0M
Net Profit$-66.0M$-78.0M$-52.0M$-16.0M$-2.0M
EPS$-11.40$-11.25$-6.00$-2.57$-0.39
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$125.0M$92.0M$18.0M$9.0M$18.0M
Total Liabilities$13.0M$46.0M$18.0M$13.0M$8.0M
Cash$110.0M$76.0M$6.0M$7.0M$17.0M
Borrowings$2.0M$31.0M$2.0M$1.0M$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-54.0M$-65.0M$-49.0M$-11.0M$-5.0M
Investing Cash Flow$-11.0M$-6.0M$6.0M$0$1.0M
Financing Cash Flow$-1.0M$-3.0M$0$3.0M$0
Net Cash Flow$12.0M$-34.0M$-70.0M$0$10.0M
Free Cash Flow$-59.0M$-68.0M$-50.0M$-11.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-105.42%
Quick Ratio2.10
Interest Coverage—
Return 1Y-73.56%
Return 3Y-99.76%
Return 5Y-99.97%

Ownership

Insiders Held4.30%
Institutions Held9.47%
Institutions Float Held9.89%
Institutional HolderSharesReport Date
Kestra Advisory Services, LLC176,0422026-03-31
Geode Capital Management, LLC92,7902026-03-31
Blackrock Inc.84,7452026-03-31
Citadel Advisors Llc53,2002026-03-31
Vanguard Fiduciary Trust Co32,1202026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABPAbpro Corporation $0.52 — -0.02 $1.06M 0.00%
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
DWTX $1.81 +3.14% 1.42 $3.45M 0.00%
EVGNEvogene Ltd. $0.54 -0.04% -0.41 $4.67M 0.00%

About MBIO

MBIO is led by CEO Manuel Litchman, employs 6 people, headquartered in US, publicly traded since 2017.

MBIO stock trades at $0.57 with a market capitalization of $4.32M. The stock is valued at a price-to-earnings (P/E) ratio of -1.56, price-to-book of 0.46, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.53 and $7.00, and currently trades 91.9% below its 52-week high.

On profitability, MBIO generates a return on equity (ROE) of -20.00%, return on capital employed of -20.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides